Interobserver and intraobserver variability in the response evaluation of cancer therapy according to RECIST and WHO-criteria. - Wikidata - awgldk - TriplyDB

Interobserver and intraobserver variability in the response evaluation of cancer therapy according to RECIST and WHO-criteria.

Interobserver and intraobserver variability in the response evaluation of cancer therapy according to RECIST and WHO-criteria.

http://www.wikidata.org/entity/Q53066813

about

Somatic mutations associated with MRI-derived volumetric features in glioblastoma Intraobserver and interobserver variability in computed tomography size and attenuation measurements in patients with renal cell carcinoma receiving antiangiogenic therapy: implications for alternative response criteria.RECIST measurements in cancer treatment: is there a role for physician assistants? - A pilot study.Interobserver agreement of semi-automated and manual measurements of functional MRI metrics of treatment response in hepatocellular carcinoma.Assessment of Volumetric versus Manual Measurement in Disseminated Testicular Cancer; No Difference in Assessment between Non-Radiologists and Genitourinary Radiologist Evaluation of a cloud-based local-read paradigm for imaging evaluations in oncology clinical trials for lung cancer Comparison of Existing Response Criteria in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Using a 3D Quantitative Approach.Comparison of semi-automatic volumetric VX2 hepatic tumor segmentation from cone beam CT and multi-detector CT with histology in rabbit models Semiautomatic volumetric tumor segmentation for hepatocellular carcinoma: comparison between C-arm cone beam computed tomography and MRI.Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part I. Identification and validation of volumetric functional response criteria Interreader and inter-test agreement in assessing treatment response following transarterial embolization for hepatocellular carcinoma Identification of Discrete Prognostic Groups in Ewing Sarcoma Observer variability in a phase II trial - assessing consistency in RECIST application.Assessment of treatment response in hepatocellular carcinoma: a review of the literature.Childhood extracranial neoplasms: the role of imaging in drug development and clinical trials.Colorectal cancer with Synchronous liver-limited Metastases: the protocol of an Inception Cohort study (CoSMIC).Three-dimensional Radiologic Assessment of Chemotherapy Response in Ewing Sarcoma Can Be Used to Predict Clinical Outcome.Interventional Oncology in Hepatocellular Carcinoma: Progress Through Innovation.New concepts in embolotherapy of HCC.A multicentre comparison between Child Pugh and Albumin-Bilirubin scores in patients treated with sorafenib for Hepatocellular Carcinoma.Parametric response mapping of dynamic CT: enhanced prediction of survival in hepatocellular carcinoma patients treated with transarterial chemoembolization.Measurements of metastatic renal cell tumours as determined by diffusion weighted imaging or computed tomography are in close agreement, a pilot study.Imaging texture analysis for automated prediction of lung cancer recurrence after stereotactic radiotherapy.A fully automatic end-to-end method for content-based image retrieval of CT scans with similar liver lesion annotations.Prognostic relevance of early radiologic response to induction chemotherapy in pediatric rhabdomyosarcoma: A report from the International Society of Pediatric Oncology Malignant Mesenchymal Tumor 95 study.Intra- and inter-observer agreement in the visual interpretation of interim 18F-FDG PET/CT in malignant lymphoma: influence of clinical information.Yttrium-90 radioembolization treatment for unresectable hepatocellular carcinoma: a single-centre prognostic factors analysis.Reproducibility of mRECIST in assessing response to transarterial radioembolization therapy in hepatocellular carcinoma.Reply to 'Statistical controversies in clinical research: end points other than survival are vital for regulatory approval of anticancer agents' by Saad and Buyse.

P2860

Q28607337-8688ACDF-2628-4E05-9679-69F1564A7CC1 Q33652589-75D9F486-F303-4A29-847D-4AC2060F7B43 Q35093227-09D3A4B3-9F07-4730-B106-E26561BF3B54 Q35234472-81DFE55E-747E-4F3D-BA3E-52AE019967C1 Q36247638-A89E8929-8BD7-4901-AD3E-61966C1BA5F0 Q36345062-33007A4E-88CF-4CF1-BBD1-D0B2F8EC910E Q36416250-A377C9C3-3C24-4FBC-8736-5E0782AC409F Q36617564-C7CDE313-622A-4541-9C2B-4B471CDCBCE7 Q36700219-0B20DC57-C56D-4A94-A0F7-C3EEB43CE16E Q37039550-8E82D05D-4C68-43B1-9416-67A419C86755 Q37143017-619E92C5-EF7F-4C4B-BC6B-BB74E32DCFE0 Q37232948-642647B2-D979-4491-9631-70E9454439FD Q37995235-884FC024-3981-4AD2-B853-534BA39AE9AC Q38110321-69E80AC0-8A41-48CB-8A5D-7A60735B087F Q38516659-7C827F55-DAB7-49A5-A0EA-81DC86F54B24 Q38732104-718A10D0-D15D-45B3-A7EB-8B2D38D367AB Q38777057-7C033A73-F022-495B-81D4-8A175C34E49E Q38792625-02CF0FB4-68E5-4CD0-A924-70515799A3DD Q38904263-44486AD0-5CFE-4021-AA91-0E8BB8DB2A88 Q39743925-B9AF9C6D-424C-4AA4-8241-EF6E759AAC11 Q40333754-9B6D6644-A48D-4E28-8F54-2147660CA02A Q42291319-210A27E0-9139-4FCD-8AD4-02BF5D712BE7 Q42686718-5FF28DD9-B360-44D1-AE3D-B0FD82A4458C Q47339047-24C30AF2-4B44-45DA-8C8A-E74601F1606D Q47358394-2CB1E090-5851-4097-9C24-E6D902DF9272 Q50047838-3B3F4551-D44F-433F-A1D1-6807AF9F8A13 Q50218004-1E00DA5A-D6C8-4716-9101-3087DC33A702 Q53173190-7C711A1D-151E-4AB9-990C-DEB2D863B656 Q54463022-B30D8C8E-50BD-4519-A669-3FA0717D409D

P2860

Interobserver and intraobserver variability in the response evaluation of cancer therapy according to RECIST and WHO-criteria.

http://www.wikidata.org/entity/Q53066813

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh-hant

name

Interobserver and intraobserve ...... ng to RECIST and WHO-criteria.

@en

Interobserver and intraobserve ...... ng to RECIST and WHO-criteria.

@nl

type

label

Interobserver and intraobserve ...... ng to RECIST and WHO-criteria.

@en

Interobserver and intraobserve ...... ng to RECIST and WHO-criteria.

@nl

prefLabel

Interobserver and intraobserve ...... ng to RECIST and WHO-criteria.

@en

Interobserver and intraobserve ...... ng to RECIST and WHO-criteria.

@nl

P1433

Q53066813-313C9435-374C-453A-820D-846E55632CBF

P1476

Q53066813-219DD5C5-3F6F-45A8-B246-03A20D69D8BC

P2093

Q53066813-07867D6A-DED1-4565-8ADB-1198C858E980

Q53066813-106E2111-2F3E-465A-A58B-6BCD4CDF4BDB

Q53066813-6EAC1B4D-4F31-4E37-B83A-F8DFBE7AD78B

Q53066813-99D5E4FD-64F9-4363-BF05-3AF283241754

Q53066813-A582F95C-ABB0-49F1-9731-8EF7A84FC1A2

Q53066813-B350C4CA-D88E-49A9-9333-8FED652F2EBA

Q53066813-EE4FD0CD-8CD1-40FA-8834-48AFFFC8D7DE

P2860

Q53066813-29855C6D-FE2E-4832-8EBF-C49BA24E0B02

Q53066813-39DD9C00-E695-4274-8F2E-F917F99B5E98

Q53066813-3D351EEA-63CE-4992-8C1D-7F36BE791E11

Q53066813-57770C2B-A51A-4CA0-B3AA-AD6966289838

Q53066813-8286F9C7-7E2A-4461-8C9C-D18FF5CAD637

Q53066813-83F6562A-6DFA-4BD7-8E0B-A77DEFE72C44

Q53066813-9F9FC5B9-AA07-4B78-8874-6803C4391E0D

Q53066813-CA263B3C-9D6C-4F01-927E-70F59201C30A

Q53066813-D8DF4A52-6D1E-4136-9F06-0C6AC85EF2A1

Q53066813-DB595819-DB34-4D44-85BA-4899E3FFBF08

P304

Q53066813-72BE390E-13DA-41E0-98EF-2EE062BF9609

P31

Q53066813-718FA80D-50F3-4A89-970D-BE9CEBC8D264

P356

Q53066813-8D45E775-807B-4724-B334-C837E64EADAF

P433

Q53066813-F19E5E4A-597E-4264-A4D2-94BB98C6786F

P478

Q53066813-0A18ACC3-AFCB-4116-874E-35BEECD9092D

P50

Q53066813-C496CA9B-1340-4050-BE25-C0D95E15B990

P577

Q53066813-C7B12673-7109-4429-AC95-A276F63E6632

P5875

Q53066813-8B065034-0188-4637-8BC0-01C1C9D8F7D2

P698

Q53066813-5B54A2F2-9347-4FEC-B1FF-B1878C9D9E6F

P356

02841861003705794

P1433

Acta Oncologica

P1476

Interobserver and intraobserve ...... ing to RECIST and WHO-criteria

@en

P2093

Anders Sundin

http://www.w3.org/2001/XMLSchema#string

Gunnar Aström

http://www.w3.org/2001/XMLSchema#string

Hans Jacobsson

http://www.w3.org/2001/XMLSchema#string

Hirofumi Fujii

http://www.w3.org/2001/XMLSchema#string

Lennart Blomqvist

http://www.w3.org/2001/XMLSchema#string

Michael R Torkzad

http://www.w3.org/2001/XMLSchema#string

Thomas Hatschek

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Assessment of tumour response to chemotherapy for metastatic colorectal cancer: accuracy of the RECIST criteria.

Measurement of observer agreement.

Pulmonary metastases: effect of CT section thickness on measurement--initial experience.

CT of colon cancer metastases to the liver using modified RECIST criteria: determining the ideal number of target lesions to measure.

Assessment of interobserver reproducibility in quantitative 18F-FDG PET and CT measurements of tumor response to therapy.

Semi-automated volumetric analysis of lymph node metastases in patients with malignant melanoma stage III/IV--a feasibility study.

CT assessment of tumour response to treatment: comparison of linear, cross-sectional and volumetric measures of tumour size.

Measuring response in solid tumors: comparison of RECIST and WHO response criteria.

P304

509-514

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/02841861003705794

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

49

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

43180443

http://www.w3.org/2001/XMLSchema#string

P698

20397778

http://www.w3.org/2001/XMLSchema#string